Nitric oxide as the final metabolic mediator of cervical ripening.
Chwalisz
K
K
Research Laboratories of Schering AG, Berlin, Germany.
Garfield
R E
RE
D000818:Animals; D002584:Cervix Uteri / Q000502:physiology*; D005260:Female; D006801:Humans; D007747:Labor Stage, First / Q000502:physiology*; D008954:Models, Biological; D009569:Nitric Oxide / Q000502:physiology*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors / Q000502:physiology; D052247:Nitric Oxide Synthase Type II; D007752:Obstetric Labor, Premature / Q000209:etiology / Q000503:physiopathology; D011247:Pregnancy; D011374:Progesterone / Q000502:physiology; D011451:Prostaglandin-Endoperoxide Synthases / Q000502:physiology; D011453:Prostaglandins / Q000502:physiology; D002581:Uterine Cervical Incompetence / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D014590:Uterine Contraction / Q000502:physiology
D011453:Prostaglandins; D009569:Nitric Oxide; D011374:Progesterone; C496319:NOS2 protein, human; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; D011451:Prostaglandin-Endoperoxide Synthases